Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
Open Access
- 4 November 2014
- journal article
- review article
- Published by Springer Nature in Thrombosis Journal
- Vol. 12 (1) , 24
Abstract
Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment of thromboembolic diseases. However, these agents are associated with limitations, such as the need for regular coagulation monitoring (VKAs and UFH) or a parenteral route of administration (UFH, LMWHs and fondaparinux). Several non-VKA oral anticoagulants (NOACs) are now widely used in the prevention and treatment of thromboembolic diseases and in stroke prevention in non-valvular atrial fibrillation. Unlike VKAs, NOACs exhibit predictable pharmacokinetics and pharmacodynamics. They are therefore usually given at fixed doses without routine coagulation monitoring. However, in certain patient populations or special clinical circumstances, measurement of drug exposure may be useful, such as in suspected overdose, in patients experiencing a hemorrhagic or thromboembolic event during the treatment’s period, in those with acute renal failure, in patients who require urgent surgery or in case of an invasive procedure. This article aims at providing guidance on laboratory testing of classic anticoagulants and NOACs.Keywords
This publication has 201 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient dataThe Lancet, 2012
- Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum periodAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2011
- Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variabilityJournal of Thrombosis and Thrombolysis, 2011
- Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patientsThrombosis Research, 2010
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- Drug interactions with warfarin: what clinicians need to knowCanadian Medical Association Journal, 2007
- Daily vitamin K supplementation improves anticoagulant stabilityJournal of Thrombosis and Haemostasis, 2007
- Estimating the prevalence of renal insufficiency in seniors requiring long-term careKidney International, 2004